Drug · CHEMBL100
LEVCROMAKALIM
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LEVCROMAKALIM. Drugs and targets, record CHEMBL100. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL100
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases4
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| migraine disorder | Unknown | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005277 |
| migraine with aura | Unknown | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005475 |
| migraine without aura | Unknown | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0100431 |
| chronic obstructive pulmonary disease | Preapproval | TTD | 1 | 0 | https://conductscience.org/library/drugs?q=MONDO_0005002 |
Source Open Targets
Trials12
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT05093582 | The Effects of Levcromakalim in Patients With Cluster Headache | 41 | levcromakalim | Its name | ClinicalTrials.gov | ||
| NCT04853797 | Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM) | 37 | levcromakalim | Its name | ClinicalTrials.gov | ||
| NCT04905654 | Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura | 35 | levcromakalim | Its name | ClinicalTrials.gov | ||
| NCT05211050 | Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine | 24 | levcromakalim | Its name | ClinicalTrials.gov | ||
| NCT05243953 | Hypersensitivity to Opening of ATP-Sensitive Potassium Channels in Post-Traumatic Headache | 21 | levcromakalim | Its name | ClinicalTrials.gov | ||
| NCT03609008 | The Effect of Levcromakalim Infusion on the Cranial Arteries Over Several Hours Using a High Resolution MRA Technique in a Randomized, Double-blind Placebo-controlled Design in Healthy Volunteers. | 20 | levcromakalim | Its name | ClinicalTrials.gov | ||
| NCT03726242 | Peripheral Nociceptive Effects of Levcromakalim | 20 | levcromakalim | Its name | ClinicalTrials.gov | ||
| NCT05565001 | The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. | 20 | levcromakalim | Its name | ClinicalTrials.gov | ||
| NCT04012047 | Headache Inducing Effect of Levcromakalim in Migraine With Aura Patients | 17 | levcromakalim | Its name | ClinicalTrials.gov | ||
| NCT03228355 | Headache Inducing Effect of Cromakalim in Migraine Patients | 16 | levcromakalim | Its name | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials11
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 41930571 | DERIVED | 1 | PubMed |
| 40624944 | DERIVED | 1 | PubMed |
| 39161224 | DERIVED | 1 | PubMed |
| 38501895 | DERIVED | 1 | PubMed |
| 38181724 | DERIVED | 1 | PubMed |
| 38127692 | DERIVED | 1 | PubMed |
| 37917826 | DERIVED | 1 | PubMed |
| 33768245 | DERIVED | 1 | PubMed |
| 32806954 | DERIVED | 1 | PubMed |
| 31535367 | DERIVED | 1 | PubMed |
1 to 10 of 11
See all 11 papers from its trialsTests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL100
GET https://conductscience.org/api/drugs/v1/CHEMBL100/targets